Tourette syndrome is a neurodevelopmental disorder defined by both multiple motor tics AND one or more vocal tics, with onset before age 18 and duration over 1 year. Tics wax and wane in frequency and severity; their character may change over time. Typical onset between ages 4-7 with peak severity in early adolescence; many patients improve substantially by adulthood.
Tics are sudden, rapid, recurrent, non-rhythmic motor movements or vocalizations. Motor: eye blinking, facial grimacing, head jerks, shoulder shrugs, more complex movements. Vocal: throat clearing, sniffing, grunting, in severe cases coprolalia (involuntary obscenities — uncommon, popularly overrepresented). Tics are typically preceded by a premonitory urge — a building sensation that the tic relieves.
Brief suppression is possible. Patients can hold back tics for periods (in social situations, during exams) but typically experience increasing urge and eventual release in a rebound. The suppressibility distinguishes tics from many other movement disorders.
Comorbidity is the rule, not the exception. ADHD co-occurs in 50-70% of Tourette patients; OCD in 30-40%. Anxiety, depression, learning difficulties, and impulse control problems are common. Often the comorbid conditions cause more functional impairment than the tics themselves.
The neuroanatomy: basal ganglia hyperactivity in motor and limbic cortico-striato-thalamo-cortical loops. The action-gating system intermittently fails, allowing unwanted motor sequences (tics) and vocal sequences to escape inhibition. Within the OC spectrum given shared basal ganglia involvement and high OCD comorbidity.
First-line treatment: Comprehensive Behavioral Intervention for Tics (CBIT). Three components: awareness training (recognizing premonitory urges), competing response (a deliberate behavior incompatible with the tic, performed when urge arises), functional intervention (modifying environments and contingencies that worsen tics). CBIT has demonstrated efficacy comparable to medication without side effects.
Pharmacotherapy for severe tics: Alpha-2 agonists (clonidine, guanfacine) first-line — also help comorbid ADHD. Antipsychotics (aripiprazole, risperidone) second-line, with attention to side effects particularly in pediatric populations. VMAT2 inhibitors (tetrabenazine, deutetrabenazine) for refractory cases. Botulinum toxin for focal severe tics. Deep brain stimulation for severe refractory adult cases.
When you encounter a patient with motor and vocal tics, the diagnosis is Tourette syndrome and the treatment toolkit is broad. CBIT first; pharmacology when severity demands. Treatment of comorbid ADHD and OCD often produces more functional improvement than tic suppression alone.